title: Organotypic cultures as tools for optimizing central nervous system cell therapies.
abstract: Stem cell therapy is a promising treatment for neurological disorders such as cerebral ischemia, Parkinson's disease and Huntington's disease. In recent years, many clinical trials with various cell types have been performed often showing mixed results. Major problems with cell therapies are the limited cell availability and engraftment and the reduced integration of grafted cells into the host tissue. Stem cell-based therapies can provide a limitless source of cells but survival and differentiation remain a drawback. An improved understanding of the behaviour of stem cells and their interaction with the host tissue, upon implantation, is needed to maximize the therapeutic potential of stem cells in neurological disorders. Organotypic cultures made from brain slices from specific brain regions that can be kept in culture for several weeks after injecting molecules or cells represent a remarkable tool to address these issues. This model allows the researcher to monitor/assess the behaviour and responses of both the endogenous as well as the implanted cells and their interaction with the microenvironment leading to cell engraftment. Moreover, organotypic cultures could be useful to partially model the pathological state of a disease in the brain and to study graft-host interactions prior to testing such grafts for pre-clinical applications. Finally, they can be used to test the therapeutic potential of stem cells when combined with scaffolds, or other therapeutic enhancers, among other aspects, needed to develop novel successful therapeutic strategies or improve on existing ones.
authors.affiliation: INSERM U1066, 'Micro et Nanomédecines biomimétiques-MINT', Angers, France; LUNAM Université, Université Angers, UMR-S1066, Angers, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Daviaud
authors.forename: Elisa
authors.initials: E
authors.lastname: Garbayo
authors.forename: Paul C
authors.initials: PC
authors.lastname: Schiller
authors.forename: Miguel
authors.initials: M
authors.lastname: Perez-Pinzon
authors.forename: Claudia N
authors.initials: CN
authors.lastname: Montero-Menei
mesh_terms: D000818:Animals; D002490:Central Nervous System / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D019636:Neurodegenerative Diseases / Q000628:therapy*; D009474:Neurons / Q000166:cytology* / Q000378:metabolism; D009924:Organ Culture Techniques / Q000379:methods*; D033581:Stem Cell Transplantation / Q000379:methods*; D023822:Tissue Engineering
keywords: 1, 3, di-o-tolylguanidine; 1-methyl-4-phenylpyridium; 3-NPA; 3-nitropropionic acid; 6-OHDA; 6-hydroxydopamine; CA1; CI; CNS; Cell behaviour; Cell therapy; Cornu Ammonis layer 1; DA; DTG; EGF; ES; GABA; HD; HUCBC; Huntington's disease; KA; MPP+; MSC; MSN; N-methyl-d-aspartic acid; NGF; NMDA; NSC; NT-3; Neurodegenerative disorders; OGD; Organotypic slices; PAMs; PD; Parkinson's disease; QA; SN; Stem cells; TH; Tissue engineering; bFGF; basic fibroblast growth factor; central nervous system; cerebral ischemia; dopamine; embryonic stem; epidermal growth factor; gamma-aminobutyric acid; human umbilical cord blood stem cells; iPS cells; induced-pluripotent stem; kainic acid; medium spiny neuron; mesenchymal stromal cells; nerve growth factor; neural stem cells; neurotrophin-3; oxygen-glucose-deprivation; pharmacologically active microcarriers; polyQ; polyglutamine; quinolinic acid; substancia nigra; tyrosine hydroxylase